Dr. Martin Lunnon initially undertook a BSc in Chemistry at Bristol. He always had the intention to stay on for a PhD and wanted to work on something with biological relevance. So he selected to research for a PhD in Bio-organic Chemistry, mainly working on gibberellin plant hormones, but also using 13C NMR to study biosynthesis. What he enjoyed about this was working in a multidisciplinary group. There was both academic and commercial relevance to the work, his thesis supervisor at Bristol had also worked in Industry. All the above helped prepare him for a career in the Pharmaceutical Industry. He has worked in the Pharmaceutical Industry for 40 years, everywhere from Molecule to Market Place, however, the vast majority of this has been in Early Phase Clinical Development. He is a Clinical Pharmacologist. He is a member of the Brit Pharmacol Soc (BPS), has been a BPS Clinical Committee Member and occasional reviewer for Br J Clin Pharmacol. He was Chairman of the Former Society of Pharmaceutical Medicine. His experience extends across a variety of therapeutic areas, but a good part in CVS/CNS. He was made an honorary Member of the Faculty of Pharmaceutical Medicine (RCP) in 2001. He has worked for British, Swiss, French, American and Japanese companies. He now advises a couple of small companies developing drugs for rare neurological diseases. In 2015 he was appointed visiting Senior Lecturer at King’s College London (Waterloo Campus), in the Institute of Pharmaceutical Sciences; he teaches on the MSc courses within this Department.

Dr. Lunnon’s research interests include cardiovascularand neurological clinical pharmacology; applying science to clinical problems; translational medicine /surrogate endpoints, both biomarkers and imaging; assessing concentration/effect.